BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18850583)

  • 1. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.
    Uddin S; Hussain A; Ahmed M; Belgaumi A; Al-Dayel F; Ajarim D; Bavi P; Al-Kuraya KS
    J Pathol; 2008 Dec; 216(4):483-94. PubMed ID: 18850583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.
    Uddin S; Ahmed M; Hussain AR; Jehan Z; Al-Dayel F; Munkarah A; Bavi P; Al-Kuraya KS
    Lab Invest; 2009 Oct; 89(10):1115-27. PubMed ID: 19636294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
    Uddin S; Hussain AR; Ahmed M; Siddiqui K; Al-Dayel F; Bavi P; Al-Kuraya KS
    Haematologica; 2012 Jul; 97(7):1092-100. PubMed ID: 22271891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.
    Lwin T; Hazlehurst LA; Dessureault S; Lai R; Bai W; Sotomayor E; Moscinski LC; Dalton WS; Tao J
    Blood; 2007 Sep; 110(5):1631-8. PubMed ID: 17502456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of Skp2 expression in Egyptian diffuse large B-cell lymphoma.
    Abdou AG; Asaad NY; Abd El-Wahed MM; Samaka RM; Allah MS
    Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):47-55. PubMed ID: 21558842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SKP2 siRNA inhibits the degradation of P27kip1 and down-regulates the expression of MRP in HL-60/A cells.
    Xiao J; Yin S; Li Y; Xie S; Nie D; Ma L; Wang X; Wu Y; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2009 Aug; 41(8):699-708. PubMed ID: 19657571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.
    Huang HC; Way TD; Lin CL; Lin JK
    Endocrinology; 2008 Dec; 149(12):5972-83. PubMed ID: 18719023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.
    Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Begum R; Melosantos R; Al-Sobhi SS; Al-Dawish M; Al-Dayel F; Al-Kuraya KS
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1530-1544. PubMed ID: 29300929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway.
    Foster JS; Fernando RI; Ishida N; Nakayama KI; Wimalasena J
    J Biol Chem; 2003 Oct; 278(42):41355-66. PubMed ID: 12904306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells.
    Hussain AR; Ahmed M; Ahmed SO; Al-Thari S; Khan AS; Razack S; Platanias LC; Al-Kuraya KS; Uddin S
    Leuk Lymphoma; 2009 Jul; 50(7):1204-13. PubMed ID: 19557642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo.
    Katagiri Y; Hozumi Y; Kondo S
    J Dermatol Sci; 2006 Jun; 42(3):215-24. PubMed ID: 16504485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation.
    Kudo Y; Kitajima S; Ogawa I; Kitagawa M; Miyauchi M; Takata T
    Mol Cancer Ther; 2005 Mar; 4(3):471-6. PubMed ID: 15767556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma.
    Seki R; Okamura T; Koga H; Yakushiji K; Hashiguchi M; Yoshimoto K; Ogata H; Imamura R; Nakashima Y; Kage M; Ueno T; Sata M
    Am J Hematol; 2003 Aug; 73(4):230-5. PubMed ID: 12879424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis.
    Calvisi DF; Ladu S; Pinna F; Frau M; Tomasi ML; Sini M; Simile MM; Bonelli P; Muroni MR; Seddaiu MA; Lim DS; Feo F; Pascale RM
    Gastroenterology; 2009 Nov; 137(5):1816-26.e1-10. PubMed ID: 19686743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells.
    Lee SH; McCormick F
    J Mol Med (Berl); 2005 Apr; 83(4):296-307. PubMed ID: 15605273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells.
    Supriatno ; Harada K; Yoshida H; Sato M
    Int J Oncol; 2005 Sep; 27(3):627-35. PubMed ID: 16077910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.